Properties of influenza viruses that caused epidemic increases in morbidity in Russia and countries of the world during 2022–2023. The effectiveness of vaccine prophylaxis

Author:

Burtseva Elena I.ORCID,Kolobukhina Ludmila V.ORCID,Panova Anna D.ORCID,Mukasheva Evgeniya A.ORCID,Krasnoslobodtsev Kirill G.ORCID,Kirillova Elena S.ORCID,Breslav Natalia V.ORCID,Trushakova Svetlana V.ORCID,Komarova Irina A.ORCID,Feodoritova Elena L.ORCID,Merkulova Liliya N.ORCID,Khlopova Irina N.ORCID,Kruzhkova Irina S.ORCID,Ignatieva Anna V.ORCID,Krepkaia Anastasia S.ORCID,Komissarov Andrey B.ORCID,Pochtovyi Andrei A.ORCID,Kustova Daria D.ORCID,Gushchin Vladimir A.ORCID,Tyurin Igor N.ORCID,Samkov Alexey A.ORCID,Antipyat Natalya А.ORCID

Abstract

The purpose of this work was to determine the characteristics of the circulation of various viral respiratory pathogens during the epidemic season 2022–2023 against the background of the ongoing evolutionary variability of SARS-CoV-2. Materials and methods. The article uses methods used in «traditional» and «hospital» epidemiological surveillance of acute respiratory viral infections. Results and discussion. The period from October 2022 to September 2023 was characterized by early and high activity of influenza A(H1N1)pdm09 virus, which was replaced by influenza B virus. The antigenic and genetic properties of strains were closely related to influenza vaccines viruses recommended by WHO experts for the current season. The effectiveness of influenza vaccines was confirmed (75.0%). All of the studied influenza A(H1N1)pdm09, A(H3N2) and B epidemic strais retained sensitivity to drugs with antineuraminidase activity. The structure and share of other ARVI pathogens have changed somewhat compared to the previous season: There was a tendency to increase the activity of HAdV and HMPV; almost equivalent activity of HRsV, HRV, HCoV and HBoV; and a decrease in HPIV activity. At the same time, the frequency of other ARVI pathogens did not reach the indicators of the pre-pandemic COVID-19 period. The rationale for updating the composition of influenza vaccines for the countries of the Northern Hemisphere in the 2023–2024 season is given.

Publisher

Central Research Institute for Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3